The fate of human Langerhans cells in hematopoietic stem cell transplantation

Journal of Experimental Medicine

Volumn 203, Issue 1, 2006, Pages 27-33

  Collin, Matthew P ^a   Hart, Derek N J ^b   Jackson, Graham H ^a   Cook, Gordon ^c   Cavet, James ^d   Mackinnon, Stephen ^e   Middleton, Peter G ^a   Dickinson, Anne M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Mater Research Institute   (Australia)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL FATE; CELL ISOLATION; CELL SURVIVAL; CHIMERA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GIEMSA STAIN; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LANGERHANS CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; T LYMPHOCYTE;

EID: 31344469849     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20051787     Document Type: Article

References (29)

1. Ferrara, J.L., K.R. Cooke, and T. Teshima. 2003. The pathophysiology of acute graft-versus-host disease. Int. J. Hematol. 78:181-187.
2. Shlomchik, W.D., M.S. Couzens, C.B. Tang, J. McNiff, M.E. Robert, J. Liu, M.J. Shlomchik, and S.G. Emerson. 1999. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 285:412-415.
3. Matte, C.C., J. Liu, J. Cormier, B.E. Anderson, I. Athanasiadis, D. Jain, J. McNiff, and W.D. Shlomchik. 2004. Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10:987-992.
4. Anderson, B.E., J.M. McNiff, D. Jain, B.R. Blazar, W.D. Shlomchik, and M.J. Shlomchik. 2005. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 105:2227-2234.
5. Merad, M., P. Hoffmann, E. Ranheim, S. Slaymaker, M.G. Manz, S.A. Lira, I. Charo, D.N. Cook, I.L. Weissman, S. Strober, and E.G. Engleman. 2004. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat. Med. 10:510-517.
6. Tamaki, K., G. Stingl, and S.I. Katz. 1980. The origin of Langerhans cells. J. Invest. Dermatol. 74:309-311.
7. Merad, M., M.G. Manz, H. Karsunky, A. Wagers, W. Peters, I. Charo, I.L. Weissman, J.G. Cyster, and E.G. Engleman. 2002. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat. Immunol. 3:1135-1141.
8. Fearnley, D.B., L.F. Whyte, S.A. Carnoutsos, A.H. Cook, and D.N. Hart. 1999. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood. 93:728-736.
9. Klangsinsirikul, P., G.I. Carter, J.L. Byrne, G. Hale, and N.H. Russell. 2002. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood. 99:2586-2591.
10. Auffermann-Gretzinger, S., I.S. Lossos, T.A. Vayntrub, W. Leong, F.C. Grumet, K.G. Blume, K.E. Stockerl-Goldstein, R. Levy, and J.A. Shizuru. 2002. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood. 99:1442-1448.
11. Perreault, C., M. Pelletier, D. Landry, and M. Gyger. 1984. Study of Langerhans cells after allogeneic bone marrow transplantation. Blood. 63:807-811.
12. Sloane, J.P., J.A. Thomas, S.F. Imrie, D.F. Easton, and R.L. Powles. 1984. Morphological and immunohistological changes in the skin in allogeneic bone marrow recipients. J. Clin. Pathol. 37:919-930.
13. Murphy, G.F., Y. Merot, A.K. Tong, B. Smith, and M.C. Mihm Jr. 1985. Depletion and repopulation of epidermal dendritic cells after allogeneic bone marrow transplantation in humans. J. Invest. Dermatol. 84:210-214.
14. Atkinson, K., V. Munro, E. Vasak, and J. Biggs. 1986. Mononuclear cell subpopulations in the skin defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. Br. J. Dermatol. 114:145-160.
15. Volc-Platzer, B., G. Stingl, K. Wolff, W. Hinterberg, and W. Schnedl. 1984. Cytogenetic identification of allogeneic epidermal Langerhans cells in a bone-marrow-graft recipient. N. Engl. J. Med. 310:1123-1124.
16. Perreault, C., M. Pelletier, R. Belanger, J. Boileau, Y. Bonny, M. David, M. Gyger, D. Landry, and S. Montplaisir. 1985. Persistence of host Langerhans cells following allogeneic bone marrow transplantation: possible relationship with acute graft-versus-host disease. Br. J. Haematol. 60:253-260.
17. Czernielewski, J.M., and M. Demarchez. 1987. Further evidence for the self-reproducing capacity of Langerhans cells in human skin. J. Invest. Dermatol. 88:17-20.
18. Kanitakis, J., P. Petruzzo, and J.M. Dubernard. 2004. Turnover of epidermal Langerhans' cells. N. Engl. J. Med. 351:2661-2662.
19. Mielcarek, M., P.J. Martin, W. Leisenring, M.E. Flowers, D.G. Maloney, B.M. Sandmaier, M.B. Maris, and R. Storb. 2003. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 102:756-762.
20. Marks, D.I., R. Lush, J. Cavenagh, D.W. Milligan, S. Schey, A. Parker, F.J. Clark, L. Hunt, J. Yin, S. Fuller, et al. 2002. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 100:3108-3114.
21. Peggs, K.S., K. Thomson, D.P. Hart, J. Geary, E.C. Morris, K. Yong, A.H. Goldstone, D.C. Linch, and S. Mackinnon. 2004. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 103:1548-1556.
22. Shlomchik, W.D. 2003. Antigen presentation in graft-vs-host disease. Exp. Hematol. 31:1187-1197.
23. Merad, M. 2005. Ontogeny of Langerhans cells and graft versus host disease. Adv. Exp. Med. Biol. 560:115-123.
24. Ratzinger, G., J.L. Reagan, G. Heller, K.J. Busam, and J.W. Young. 2003. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. 101:1422-1429.
25. Collin, M.P., D. Munster, G. Clark, X.N. Wang, A.M. Dickinson, and D.N. Hart. 2005. In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of Graft-versus-host disease. Transplantation. 79:722-725.
26. Perez-Simon, J.A., P.D. Kottaridis, R. Martino, C. Craddock, D. Caballero, R. Chopra, J. Garcia-Conde, D.W. Milligan, S. Schey, A. Urbano-Ispizua, et al. 2002. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 100:3121-3127.
27. Mapara, M.Y., Y.M. Kim, S.P. Wang, R. Bronson, D.H. Sachs, and M. Sykes. 2002. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: chimeras: a critical role for host antigen-presenting cells. Blood. 100:1903-1909.
28. Barrett, A.J., D. Mavroudis, J. Tisdale, J. Molldrem, E. Clave, C. Dunbar, M. Cottler-Fox, S. Phang, C. Carter, P. Okunnieff, et al. 1998. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant. 21:543-551.
29. Baron, F., J.E. Baker, R. Storb, T.A. Gooley, B.M. Sandmaier, M.B. Maris, D.G. Maloney, S. Heimfeld, D. Oparin, E. Zellmer, et al. 2004. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 104:2254-2262.